BMC
PTCT icon

Bear Mountain Capital’s PTC Therapeutics PTCT Stock Holding History

Bear Mountain Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8
Closed -$537 – 289
2025
Q3 		$537 Buy
+8
New +$417 ﹤0.01% 190

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bear Mountain Capital's PTCT Position: Q4 2025 in Review

Bear Mountain Capital sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 8 shares — an estimated $537 sold.

Bear Mountain Capital first reported a position in PTCT in Q3 2025 and held it in 1 quarter. The position peaked at $537 in Q3 2025. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • Bear Mountain Capital reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bear Mountain Capital sold 8 PTC Therapeutics shares in Q4 2025, an estimated $537.
  • Bear Mountain Capital first reported a position in PTC Therapeutics in Q3 2025 and held it in 1 quarter.
  • Bear Mountain Capital's PTC Therapeutics position peaked at $537 in Q3 2025.
  • 353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Bear Mountain Capital's 13F filing for Q4 2025, filed 22 Jan 2026.